PMVP - PMV Pharmaceuticals, Inc.
IEX Last Trade
1.46
-0.055 -3.767%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:19:15 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$1.52
-0.06
-3.63%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-2.00%
1 Month
-7.55%
3 Months
-1.34%
6 Months
-12.50%
1 Year
-50.84%
2 Year
-83.16%
Key data
Stock price
$1.46
DAY RANGE
$1.50 - $1.52
52 WEEK RANGE
$1.49 - $3.47
52 WEEK CHANGE
-$54.91
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: David H. Mack
Region: US
Website: pmvpharma.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: pmvpharma.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
PMV Pharmaceuticals, Inc. engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function.
Recent news